Abundant structural information exists on how thrombin recognizes ligands at the active site or at exosites separate from the active site region, but remarkably little is known about how thrombin recognizes substrates that bridge both the active site and exosite I. The case of the protease-activated receptor PAR1 is particularly relevant in view of the plethora of biological effects associated with its activation by thrombin. Here, we present the 1.8 Å resolution structure of thrombin S195A in complex with a 30-residue long uncleaved extracellular fragment of PAR1 that documents for the first time a productive binding mode bridging the active site and exosite I. The structure reveals two unexpected features of the thrombin-PAR1 interaction. The acidic P3 residue of PAR1, Asp 39 , does not hinder binding to the active site and actually makes favorable interactions with Gly 219 of thrombin. The tethered ligand domain shows a considerable degree of disorder even when bound to thrombin. The results fill a significant gap in our understanding of the molecular mechanisms of recognition by thrombin in ways that are relevant to other physiological substrates.
Thrombin is a trypsin-like protease endowed with important physiological functions that are mediated and regulated by interaction with numerous macromolecular substrates, receptors, and inhibitors (1). Fenton (2) was the first to recognize that thrombin selectivity toward macromolecular substrates depends on interactions with exosites that extend beyond the active site. Exosite I is positioned some 15 Å away from the active site (3) and occupies a domain analogous to the Ca 2ϩ -binding loop of trypsin and chymotrypsin (4) . Recognition of macromolecular substrates or receptors responsible for the procoagulant, prothrombotic, signaling, and anticoagulant functions of thrombin depends on the structural integrity of this exosite (1) . In general, exosite-dependent binding is kinetically limiting as a recognition strategy of macromolecular targets by enzymes involved in blood coagulation (5) . Structural and site-directed mutagenesis data document the important role of exosite I in the interaction of thrombin with fibrinogen (6 -9) and the protease-activated receptors (PARs) 2 PAR1 (7, 10 -13) and PAR3 (7, 14, 15) . Likewise, abundant structural and functional data document how thrombin recognizes substrates at the active site (3, 16, 17) , including fibrinogen (18) , PAR4 (15, 19) , and factor XIII (20, 21) . On the other hand, structural elucidation of how substrates bridge the active site and exosite I in their binding to thrombin has been challenging. PAR1 is a premiere prothrombotic and signaling factor (22) , the most specific physiological substrate of thrombin in terms of k cat /K m values (7), and a most relevant target for crystallization studies. PARs are members of the G-protein-coupled receptor superfamily and play important roles in blood coagulation, inflammation, cancer, and embryogenesis (23) (24) (25) (26) (27) (28) . Four PARs have been cloned, and they all share the same mechanism of activation (22, 26, 29) : thrombin and other proteases derived from the circulation and inflammatory cells cleave at a specific site within the extracellular N terminus to expose a new N-terminal tethered ligand domain, which binds to and activates the cleaved receptor (30) . Thrombin activates PAR1 (10), PAR3 (14, 24) , and PAR4 (31) (32) (33) in this manner but has no specificity toward PAR2, which is the target of other proteases. Cleaved PAR1 also acts as a cofactor for PAR4 activation on human platelets (34) .
Major progress has been made recently in our structural understanding of how thrombin recognizes the extracellular domain of PAR4 and how cleaved PAR3 acts as a cofactor for PAR4 cleavage on murine platelets (15) . On the other hand, our structural information on the binding mode of PAR1 remains confined to the acidic hirugen-like domain, which recognizes exosite I (12, 13) as predicted by mutagenesis data (7, 10) . In a previous structure of thrombin bound to an extracellular fragment of PAR1, the cleavage site at Arg 41 was directed toward the active site of a second thrombin molecule in the crystal lattice in a nonproductive binding mode (12) . No details could be gleaned on the contacts made by the P1-P4 residues (35) of PAR1 with the active site of thrombin or on the precise conformation of the tethered ligand domain bound to the enzyme. That information is presented here for the first time.
MATERIALS AND METHODS
The human thrombin mutant S195A was constructed, expressed, and purified to homogeneity as described previously (36 42 ), was synthesized by solid phase, purified to homogeneity by high pressure liquid chromatography, and tested for purity by mass spectrometry. Thrombin S195A was concentrated to 9 mg/ml in 50 mM choline chloride and 20 mM Tris (pH 7.4). The PAR1 fragment, also in the same buffer, was added to maintain the molar ratio at 1:11. Initial crystal screening was done using the PEGs Suite (Qiagen, Valencia, CA) containing 0.2 M Na ϩ /K ϩ tartrate. Vapor diffusion with hanging drops was used to generate crystals. For each of the 96 screen conditions, a hanging drop was prepared by mixing 1 l of thrombin-PAR1 complex and 1 l of reservoir solution, and the drop was allowed to equilibrate with 500 l of crystallization buffer at 22°C. Diffraction quality crystals were obtained in 2 weeks. The crystals were triclinic, with space group P1 and unit cell parameters a ϭ 46.3 Å, b ϭ 50.2 Å, and c ϭ 85.5 Å and ␣ ϭ 76.4°, ␤ ϭ 83.9°, and ␥ ϭ 73.7°, with two molecules in the asymmetric unit. Crystals were cryoprotected with the appropriate buffer and 15% glycerol prior to flash-freezing. X-ray data were collected to 1.8 Å resolution at 100 K on an ADSC Quantum-315 CCD detector at beamline 14-BM-C of the Advanced Photon Source at Argonne National Laboratory (Argonne, IL). Data processing including indexing, integration, and scaling was performed using the HKL2000 software package (37) . The crystal structure of thrombin S195A bound to the extracellular fragment of PAR1 was solved by molecular replacement using the coordinates of thrombin bound to H-D-Phe-Pro-Arg-CH 2 Cl (Protein Data Bank code 1SHH) (17) as the search model. Refinement and electron density generation were performed with REFMAC from the CCP4 Suite (38) , and 5% of the reflections were selected randomly as a test for cross-validation. Model building was performed with COOT (39) . In the final refinement stage, TLS (translation/libration/screw) tensors modeling rigid body anisotropic temperature factors were calculated and applied to the model. Statistics for data collection and refinement are summarized in Table 1 . Atomic coordinates and structure factors have been deposited in the Protein Data Bank (code 3LU9).
RESULTS
It has long been recognized that the extracellular fragment of PAR1 carries all determinants for thrombin recognition (7, 10) and that these are the site of cleavage around Arg 41 , 38 LDPR 41 , contacting the active site and the acidic hirugen-like motif 51 KYEPF 55 engaging exosite I. It was therefore expected that PAR1 would interact with thrombin by bridging the active site and exosite I (10, 40), as first observed for the potent natural inhibitor hirudin (41) . Results from structural investigation of the thrombin-PAR1 interaction have documented the expected binding mode to exosite I (12, 13) but not the way PAR1 contacts the active site. Specifically, a previous low (3.1 Å) resolution structure of thrombin bound to a 23-residue long fragment of PAR1 encompassing the cleavage site revealed an artifactual conformation of the tethered ligand downstream of Arg 41 resulting into nonproductive contacts with a second thrombin molecule in the crystal lattice (12) . The artifactual conformation documented for PAR1 bound to thrombin in this previous structure (12) is not surprising because thrombin was used in its active wild-type form. Productive binding of the PAR1 fragment to the active site would have resulted in cleavage and either failure to crystallize or crystallization of a complex with the cleaved peptide bound. The structure presented here was solved using thrombin inactivated with the S195A mutation and reveals a binding mode of PAR1 to the E:Na ϩ (fast) form of thrombin that is consistent with all functional and mutagenesis data (7, 10) . The relatively high (1.8 Å) resolution of the present structure yields good electron density for the entire complex (Fig. 1) . The extracellular fragment of PAR1 is bound to a single thrombin molecule in the crystal, and the surface of recognition bridges the active site and exosite I, as expected (7, 10, 40) . Interestingly, the tethered ligand connecting the domains of PAR1 interacting with the active site and exosite I is for the most part disordered. Electron density is strong for Arg 41 and Ser 42 at the cleavage site, vouching for an intact PAR1 peptide, but becomes weaker for sequence 44 LLRNP 48 immediately downstream (Fig.  2) . A solution structure of the cleaved fragment of human PAR1 captured the entire tethered ligand, 42 
SFLLRNPND
50 , in a stable S-like conformation predicted to fold away from the thrombin surface (42) . Recent crystallographic data were unable to detect strong electron density for fragments 38 SFNGGP 43 and 42 SFLLRNP 48 , corresponding to the tethered ligands of murine PAR3 and human PAR1 (13, 15) . These findings, along with the current structure of the thrombin-PAR1 complex, suggest that the tethered ligand may be "under tension" in the uncleaved form of PAR1, ready to snap back onto the receptor surface and away from the enzyme as soon as cleavage at Arg 41 engages the backbone N of Leu 38 . These intramolecular interactions result in a single 3 10 -helix turn reminiscent of the architecture seen in fragments of fibrinogen and factor XIII bound to thrombin (18, 20) . The C-terminal portion of the cleavage site presents the tethered ligand within 4 Å from the thrombin surface. Pro 48 . The H-bonding network likely provides a spring-loaded mechanism to trigger the conformational transition of the tethered ligand following cleavage at Arg 41 required to engage the receptor for activation and signaling.
The extracellular fragment of PAR1 engages the active site and exosite I of thrombin with a number of polar and hydrophobic interactions (Fig. 1 ) that are summarized in (Fig. 3) . These interactions are analogous to those observed for Pro residues at the P2 positions of PAR4 (15) , factor XIII (20) , and H-D-Phe-Pro-Arg-CH 2 Cl (3, 17). The P1 residue of PAR1, Arg 41 , is involved in extensive H-bonding interactions that are observed in practically all trypsin-like proteases bound to substrate (43) (44) (45) . Two water molecules contribute to the network. w40 links NH1 of Arg 41 are solvent-exposed, and no electron density is detected for the rest of PAR1 fragment 58 DEEKN 62 , in agreement with a previous structure (13) and mutagenesis data (10).
DISCUSSION
Information on how thrombin recognizes substrate at the active site has come from the structure bound to the irreversible active site inhibitor H-D-Phe-Pro-Arg-CH 2 Cl (3). Arg at P1 ion pairs to Asp 189 in the primary specificity pocket; Pro at P2 fits snugly against Pro 60b , Pro 60c , and Trp 60d in the 60-loop; and
Phe at P3, in the D-enantiomer, makes an edge-to-face interaction with Trp 215 in the aryl-binding site. This interaction, although energetically very strong (46, 47) , is present because of the D-enantiomeric form of the P3 residue. A residue at this position in the natural L-enantiomeric form would be directed to the solvent and away from the aryl-binding site. Indeed, the catalytic activity of thrombin depends little on the nature of the P3 residue (48) . Nonetheless, the H-D-Phe-Pro-Arg-CH 2 Cl-inhibited structure reveals interactions that are relevant to recognition of natural substrates like fibrinogen (18) , PAR4 (15, 19) , and factor XIII (20, 21) . The structure of thrombin in complex with the potent natural inhibitor hirudin has revealed how thrombin recognizes ligands that bridge the active site and exosite I (41) . Hirudin blocks access to the active site of thrombin using its compact N-terminal domain and binds to exosite I via its extended acidic C-terminal domain. The mode of interaction of the C-terminal domain of hirudin was later documented in the structures of thrombin bound to hirugen (49) , fibrinogen (8, 9, 50) , PAR1 (12, 13) , PAR3 (15) , and thrombomodulin (51) . The structure presented here in the complex with the extracellular fragment of PAR1 expands our knowledge of how thrombin recognizes macromolecular substrates at both the active site and exosite I.
The P1-P4 sequence 38 LDPR 41 of PAR1 is similar to the P1-P4 sequence 166 VDPR 169 of the anticoagulant substrate protein C. Because no structure of the thrombin-protein C complex is currently available, the conformation of Asp 39 of PAR1 becomes relevant to recognition of protein C. It was originally believed that the presence of an acidic residue at the P3 position of protein C would account for the poor specificity of thrombin toward this anticoagulant substrate in the absence of the cofactor thrombomodulin (52) . It was argued that Asp at this position would clash with the side chain of Glu 192 lining the thrombin active site (3). Indeed, thrombin mutants E192Q and E192A show slightly enhanced activity toward protein C (52, 53) , and the protein C mutant in which the P3 residue Asp 167 is mutated to Phe is activated more rapidly by thrombin (54) . These observations support the idea that Asp at the P3 position of protein C hinders binding to the enzyme by electrostatically clashing with the side chain of Glu 192 . Whether thrombomodulin moves Glu 192 of thrombin or Asp 167 of protein C to produce a 1000-fold enhancement of protein C activation has long been the subject of debate (51) (52) (53) (55) (56) (57) (58) (59) (60) and will likely remain so until a structure of thrombin bound to protein C is solved in the presence and absence of thrombomodulin. PAR1 carries an Asp residue at the P3 position but, unlike protein C, is the physiological substrate cleaved by thrombin with the highest k cat /K m value (7). Therefore, the presence of Asp 39 in PAR1 is not expected to provide much hindrance to binding to the active site of thrombin. Indeed, mutation of Asp 39 to Ala compromises PAR1 cleavage by thrombin to an extent comparable with that seen with the L38A and P40A mutations (61), supporting the conclusion that the side chain of Asp 39 interacts with the thrombin active site in a way that is energetically significant. Furthermore, the thrombin mutant E192Q has normal activity toward PAR1 (7) .
The structure presented here shows that the side chain of Asp 39 makes direct and water-mediated H-bonds with the Table 2 .
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backbone N of Gly 219 of thrombin. This is an important observation for two reasons. First, it demonstrates that an acidic residue at the P3 position of substrate can be accommodated favorably within the active site of the enzyme, thereby explaining the very high specificity of thrombin toward PAR1. Second, it draws renewed attention to the way thrombin recognizes protein C and proves that Asp 167 at the P3 position of protein C cannot contact thrombin as seen for Asp 39 of PAR1. Mutagenesis data have shown that the recognition surface between thrombin and protein C changes upon thrombomodulin binding (53) and is reduced to only a few residues within the active site in the presence of cofactor. It is quite likely then that protein C approaches the active site of thrombin in a conformation that does not resemble the extended architecture seen for PAR1. The structure of thrombin bound to PAR4 has revealed how substrate can fold in a way to redirect itself away from exosite I to enable cofactor binding to that domain (15) . That strategy may be used by protein C to leave exosite I free for thrombomodulin binding.
Gly 219 assumes a potentially important role as a protein engineering target to construct thrombin variants with selective specificity toward macromolecular substrates. The interaction between O␦2 of Asp 39 and the backbone N of Gly 219 is unique to PAR1. In murine PAR4, the P3 residue is Asn instead of Asp, the ␦2 atom is N instead of O, and the side chain rotates by 39°to point away from the backbone N of Gly 219 (15) . Removing the H-bonding interaction between O␦2 of Asp 39 and the backbone N of Gly 219 with the G219P mutation, as done recently for the N143P mutant of thrombin (62) , would be of significant interest. The G219P mutant may feature selective loss of PAR1 recognition and could afford a unique reagent devoid of prothrombotic and signaling functions.
